• sv
Contact
  • About us

    About us

    Orexo is a fully integrated specialty pharmaceutical company

     

    • CEO comments
    • Objectives & Strategies
    • Key market
    • Financial information
    • Board of Directors & Management
    • Corporate Governance
    • Career
    • Meet us
    • History
  • Key Therapeutic Area

    Key Therapeutic Area

    Opioid addiction is a treatable chronic disease

  • Products

    Products

    Developed 4 products approved worldwide

    • Zubsolv®
    • Abstral®
    • Edluar®
  • Pipeline

    Pipeline

    Embracing all aspects of opioid addiction

    • Innovation
    • Technologies
    • OX124 Opioid overdose
    • OX125 Opioid overdose
    • OX338 Acute moderate to severe pain
    • OX382 Opioid dependence
    • OX-MPI Microvasular disease
    • OXD01 Opioid Use Disorder
    • OXD02 Alcohol Use Disorder
  • Sustainability

    Sustainability

    We will be recognized for the added value our products bring to patients and societies

    • Our team
    • People and society
    • Opioid crisis
    • Our commitments
  • Investors

    Investors

    Orexo’s share is listed on Nasdaq Stockholm Mid Cap and available as American Depository Receipts (ADRs) on OTCQX in the US.

    • Financial calendar & events
    • Press releases
    • News
    • Reports, presentations and audiocasts
    • Analysts
    • Subscription
    • The share
    • Value Drivers
    • Key market
    • Financial information & key figures
    • Prospectus
    • IR contact
  • Media

    Media

    Follow Orexo in social media

    • Press releases
    • News
    • Social media
    • Image bank
    • Press contact
  • Orexo
  • Investors
  • The share
Top image

Listed on Nasdaq Stockholm and OTC Market the US

  • Shareholders
  • C share
  • American Depository Receipts
Loading data...

 

# As of November 29, 2019 No. of ordinary shares  No. of ordinary C shares % of capital % of votes
1 Novo Holdings A/S 9 643 184   27.1 27.7
2 HealthCap 3 556 334   10.0 10.2
3 Arbejdsmarkedets Tillægspension (ATP) 2 040 633   5.7 5.9
4 HealthInvest Partners 1 650 000   4.6 4.7
5 Anders Walldov direct and indirectly 1 550 000   4.4 4.5
6 Avanza Pension 1 362 714   3.8 3.9
7 Orexo AB (publ)   842 971 2.4 0.2
8 Nordnet Pension Insurance 455 215   1.3 1.3
9 Lancelot Asset Management AB 450 000   1.3 1.3
10 Thomas Lundqvist 309 567   0.9 0.9
11 Danica Pension 266 559   0.7 0.8
12 Huber, Reuss & Kollegen Vermögensverwaltung 261 000   0.7 0.8
13 Evli Funds 246 965   0.7 0.7
14 XACT Funds 223 493   0.6 0.6
15 SEB Funds 202 605   0.6 0.6
Total top 15   22 218 269 842 971 64.9 64.1
Others   12 492 370 0 35.1 35.9
Total   34 710 639 842 971 100.0 100.0

In total 35 553 610 of which 34 710 639 were common shares and 842 971 C shares, and number of votes amounted to 34 794 936.

Source: Monitor by Modular Finance AB. Compiled and processed data from Euroclear, Morningstar and the Swedish Supervisory Authority, among others.

 

Our drug delivery technologies improve pharmaceuticals

 

P.O. Box 303. SE-751 05 Uppsala, Sweden

Tel. +46 (0)18 780 88 00

info@orexo.com

 

©2020

Orexo AB (publ.) – All rights reserved

Contact | Dictionary & Definitions | Privacy Policy | Legal notice | Cookie policy Orexo US

This website intends to use cookies to improve the website and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information, Read more

Accept
Disclaimer
Return Continue